Latest News

Allergists explain what's settled about epinephrine nasal spray, what's not, and how to counsel patients before anaphylaxis guidelines catch up.

APPs discuss insurance barriers, dupilumab as the default COPD biologic, depemokimab adherence advantages, and why pulmonary rehab remains critically underused.

Pulmonologists weigh in on biologic selection, mepolizumab tachyphylaxis, COPD payer barriers, and why asthma outcomes far outpace COPD in real-world practice.

Retatrutide met 80-week weight-loss endpoints in TRIUMPH-2 and TRIUMPH-3, prompting a planned FDA submission in Q1 2027.

In this Q&A following EAC 2026, Blumenthal discusses perioperative anaphylaxis risk stratification, hidden OR triggers, and penicillin allergy de-labeling.

Hear Philip Adamson, MD, MSc, discuss his path through heart failure and his work with Abbott and CVRx.

Richard Lafayette, MD, discusses how atacicept's FDA approval advances BAFF/APRIL targeting in IgA nephropathy.

Ann Marie Navar, MD, PhD, highlights enlicitide’s FDA approval for hypercholesterolemia and its potential to fundamentally change therapy.

Monopar initiated a rolling NDA submission for ALXN1840, an investigational therapy for Wilson disease targeting copper dysregulation.

Phase 2 data suggest zabopegdutide improved liver fat, stiffness, and fibrosis biomarkers within 12 weeks in adults with MASH.

If approved, encaleret will be the first treatment specifically indicated for this underrepresented patient population.

Plozasiran cut triglycerides up to 81% and reduced acute pancreatitis events in phase 3 SHASTA-3, SHASTA-4 trials for severe hypertriglyceridemia.

This Q&A highlights the significance of the FDA approval of risankizumab (Skyrizi) for psoriasis and psoriatic arthritis in pediatric patients.

Interim KONFIDENT-S data show breakthrough HAE attacks began to be relieved at a median of 1.2 hours.

FDA expands RYALTRIS® approval to children aged 6 to 11 with seasonal allergic rhinitis, based on phase 3 trial data.

Agios ends tebapivat development in sickle cell disease after phase 2 results show no differentiated benefit.

According to a recent study, nearly 32.2% of US adults are well above their LDL-C targets to avoid atherosclerotic cardiovascular disease.

After broadening eligibility criteria across several disease states and a wider age range, the new guidelines have made an estimated 87.5 million adults eligible for statins.

Stay updated with the latest healthcare breakthroughs, including FDA approvals, phase 3 data, and open-label extension results.

John Sonnenberg, PhD, outlines EMERGE trial criteria, dosing sessions, and endpoints for DT120 (lysergide) ODT 100 µg in major depressive disorder.

Newly published phase 2b RELIEVE UCCD data show strong 14 week results for duvakitug in ulcerative colitis and Crohn disease.

Marc Richards, MD, discusses how new therapies and combination treatment strategies are transforming evidence-based care for chronic kidney disease.

FDA accepted Camurus’ resubmitted CAM2029 application for acromegaly, with a target action date of December 18, 2026.